Core Viewpoint - Modern Dental (03600) shares rose over 10% following a positive earnings forecast, indicating strong anticipated growth in revenue and profit for the first half of 2025 [1] Financial Performance Summary - The company expects revenue for the first half of 2025 to be between HKD 1.775 billion and HKD 1.85 billion, representing an increase of approximately 4.3% to 8.7% compared to HKD 1.702 billion for the first half of 2024 [1] - EBITDA for the first half of 2025 is projected to be between HKD 430 million and HKD 470 million, reflecting an increase of approximately 14.5% to 25.1% from HKD 376 million in the first half of 2024 [1] - Net profit for the first half of 2025 is anticipated to range from HKD 279 million to HKD 295 million, marking an increase of approximately 30.1% to 37.6% compared to HKD 214 million for the first half of 2024 [1]

Core Viewpoint - Modern Dental Group (03600) experienced a stock price increase of over 10% following a positive earnings forecast, with a current price of 5.08 HKD and a trading volume of 1.29 million HKD [1] Financial Performance Summary - For the first half of 2025, the company expects revenue to be between 1.775 billion HKD and 1.85 billion HKD, representing an increase of approximately 4.3% to 8.7% compared to the revenue of about 1.702 billion HKD for the first half of 2024 [1] - The EBITDA for the first half of 2025 is projected to be between 430 million HKD and 470 million HKD, which indicates an increase of approximately 14.5% to 25.1% from the EBITDA of about 376 million HKD for the first half of 2024 [1] - The net profit for the first half of 2025 is anticipated to be between 279 million HKD and 295 million HKD, reflecting an increase of approximately 30.1% to 37.6% compared to the net profit of about 214 million HKD for the first half of 2024 [1]

收益增长主要得益于欧洲和澳洲地区的自然增长，以及1月份收购泰国牙科实验室Hexa Ceram Company Limited（Hexa Ceram）的贡献。EBITDA和净利润的增长则归因于运营效率的提升（特别是数码化解决 方案的增加）、有利的汇率变动（欧元和澳元升值）以及对Hexa Ceram的收购。 现代牙科公告，预计2025年上半年收益将达到17.75亿至18.5亿港元，较去年同期增长4.3%至8.7%。未 计利息、税项、折旧及摊销前盈利（EBITDA）预计为4.3亿至4.7亿港元，增长14.5%至25.1%。纯利预 计为2.79亿至2.95亿港元，增长30.1%至37.6%。 （文章来源：证券时报网） ...

2025年上半年的纯利将介乎2.79亿港元至2.95亿港元，较2024年上半年的纯利约2.14亿港元，增加约 30.1%至37.6%。 收益增加主要来自集团持续的自然增长（主要在欧洲及澳洲地区），并因集团于2025年1月完成收购泰 国最大牙科实验室Hexa Ceram Company Limited（Hexa Ceram）而加速。 2025年上半年的收益将介乎17.75亿港元至18.5亿港元，较截至2024年6月30日止6个月（2024年上半年） 的收益约17.02亿港元，增加约4.3%至8.7%； 2025年上半年的未计利息、税项、折旧及摊销前盈利（EBITDA）将介乎4.3亿港元至4.7亿港元，较 2024年上半年的EBITDA约3.76亿港元，增加约14.5%至25.1%；及 来源：新浪港股 现代牙科（03600）发布公告，公司董事会谨此知会公司股东及有意投资者，基于对集团最近可得且未 经集团核数师及╱或审核委员会审核或审阅的截至2025年6月30日止6个月（2025年上半年）未经审核综 合管理账目的初步评估，集团预期： ...

Core Viewpoint - Modern Dental (03600) anticipates revenue growth for the first half of 2025, driven by natural growth and the acquisition of Hexa Ceram, with significant increases in EBITDA and net profit expected [1][2] Group 1: Financial Projections - The expected revenue for the first half of 2025 is projected to be between HKD 1.775 billion and HKD 1.85 billion, representing an increase of approximately 4.3% to 8.7% compared to HKD 1.702 billion in the first half of 2024 [1] - The anticipated EBITDA for the first half of 2025 is expected to range from HKD 430 million to HKD 470 million, which is an increase of approximately 14.5% to 25.1% from HKD 376 million in the first half of 2024 [1] - The projected net profit for the first half of 2025 is expected to be between HKD 279 million and HKD 295 million, marking an increase of approximately 30.1% to 37.6% from HKD 214 million in the first half of 2024 [1] Group 2: Growth Drivers - Revenue growth is primarily attributed to the company's ongoing natural growth, particularly in Europe and Australia [1] - The increase in EBITDA and net profit is also due to the higher proportion of digital solution cases leading to improved operational efficiency [2] - Favorable exchange rate movements, including the appreciation of the Euro and Australian Dollar against the Renminbi and Hong Kong Dollar during the period from January to June 2025, have contributed positively [2] - The acquisition of Hexa Ceram, Thailand's largest dental laboratory, has accelerated growth [1][2]

资金面上看，今日牙科医疗概念板块获主力资金净流出4.75亿元，其中，8股获主力资金净流入，净流 入资金居首的是皓宸医疗，今日主力资金净流入1.12亿元，净流入资金居前的还有美年健康、奕瑞科 技、宏盛股份等，主力资金分别净流入4540.95万元、4527.53万元、2863.59万元。 资金流入比率方面，皓宸医疗、美年健康、宏盛股份等流入比率居前，主力资金净流入率分别为 34.57%、11.58%、11.22%。（数据宝） 牙科医疗概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 002622 | 皓宸医 疗 | 9.88 | 11.13 | 11196.57 | 34.57 | | 002044 | 美年健 康 | 0.19 | 1.92 | 4540.95 | 11.58 | | 688301 | 奕瑞科 技 | 4.81 | 2.37 | 4527.53 | 10.01 | | 603090 | 宏盛股 ...

暗盘资金一眼洞悉庄家意图>> 牙科医疗板块盘初拉升，皓宸医疗（002622）封板涨停，爱迪特（301580）涨超5%，康惠制药 （603139）、悦心健康（002162）、正海生物（300653）、国瓷材料（300285）等均涨超2%。 ...

Group 1 - The A-share dental medical sector experienced a significant rise at the beginning of trading, with Haocen Medical hitting the daily limit and closing up [1] - Aidi Te rose over 5%, while Kanghui Pharmaceutical, Yueshin Health, Zhenghai Biological, and Guoci Materials all increased by more than 2.5% [1]

Core Insights - Modern Dental (03600.HK) is actively implementing multi-dimensional strategies to capture market opportunities and increase sales despite a challenging macroeconomic environment [1] - The acquisition of Thailand's largest dental laboratory, Hexa Ceram Company Limited, is expected to enhance the company's product offerings and market coverage, allowing it to outperform domestic and international competitors [1] - The company is leveraging its production facilities in Thailand, Vietnam, and Dongguan to demonstrate resilience in an uncertain international trade environment and capitalize on global digitalization trends [1] Financial Performance - For the three months ending March 31, 2025, the total revenue of the group was approximately HKD 881.11 million, representing an increase of about 5.3% compared to HKD 837.00 million for the same period in 2024 [1] - The total sales volume increased by approximately 26.6% to about 672,000 units for the three months ending March 31, 2025, compared to approximately 531,000 units for the same period in 2024 [2] - Excluding sales from Hexa Ceram, the group's sales volume increased by about 0.9% to approximately 536,000 units, while excluding Micro Dental and Hexa Ceram, the sales volume rose by about 2.1% to approximately 479,000 units [2] Digital Solutions - The contribution from Hexa Ceram included approximately 14,298 cases of digital solutions, with the total number of digital solution cases produced in China, Thailand, and Vietnam increasing to about 223,587 cases, a rise of 28.4% compared to approximately 174,193 cases in the same period of 2024 [2] - The increase in digital solution cases is attributed to more customers adopting intraoral scanners [2]

Summary of Zimvi's Conference Call Company Overview - **Company**: Zimvi - **Industry**: Dental Implants and Digital Dentistry - **Key Products**: TSX implant, T3 Pro implant, Real Guide software, Implant Concierge, Puros Allografts, Immediate Molar Implant Core Points and Arguments 1. **Market Opportunity**: In the U.S., there are approximately 8 million candidates for tooth replacement, but only 25% receive dental implants, indicating significant growth potential in the market [4][5][6] 2. **Adoption and Education**: Zimvi focuses on increasing adoption of dental implants through training and education for both staff and referring dentists, emphasizing the importance of clinical outcomes and customer experience [5][6][7] 3. **Product Innovation**: 43% of Zimvi's sales come from products launched in the last three years, showcasing a strong innovation pipeline [9][58] 4. **Digital Dentistry**: The company is investing in digital solutions, including AI and cloud-based software, to enhance workflow and patient experience, with Real Guide software seeing a 39% growth in 2024 [10][24][29] 5. **Financial Performance**: Despite headwinds, Zimvi reported a 41% improvement in EBITDA and a 238% increase in EPS, indicating strong operational efficiency [35][36] 6. **Growth Projections**: For the full year, Zimvi anticipates flat to 3% growth in top-line revenue, with adjusted EBITDA growth of 17% and adjusted EPS growth of 31% to 55% [37] Additional Important Insights 1. **Market Dynamics**: The dental implant market is underpenetrated, and Zimvi aims to capture more market share through new product introductions and improved customer relationships [8][12] 2. **Full Arch Market**: Zimvi has increased its share in the full arch market from 5% to approximately 8.5-9%, with plans to further enhance this segment [22][44] 3. **Cost Management**: The company has improved gross margins by 360 basis points through cost reductions and operational efficiencies, with aspirations to reach over 70% gross margin in the long term [50][52] 4. **Pent-Up Demand**: There is potential for pent-up demand in the dental market as consumer sentiment improves and interest rates decrease, which could lead to accelerated growth [54][56] 5. **Customer Retention**: The renewal rate for Real Guide software exceeds 90%, indicating strong customer loyalty and satisfaction [61] Conclusion Zimvi is positioned for growth in the dental implant market through strategic product innovation, digital transformation, and operational efficiencies. The company is optimistic about capturing additional market share and improving financial performance in the coming years.